Manish is Co-Founder and President of Innogenix Pharma, a generic pharmaceutical R&D and manufacturing company focused on solid oral dosage formulations, based in Long Island, New York.
He was previously Director of Business Development at Epic Pharma, a generic pharmaceutical company and CMO. While at Epic Pharma, he lead the M&A sale process in which the company was sold to Humanwell Healthcare of China in 2016.
Manish is actively involved in venture capital investing, in his capacity as CIO for a multi-family office. Areas of investment focus include: Generic pharmaceutical injectables, ophthalmic, topical, liquid, nasal, and solid oral dosage forms; Biotech from startup to public equity; and medical devices.
Prior to his experience in pharmaceuticals, Manish spent several years in finance as an analyst and trader, working in investment banking and hedge funds. He has experience investing across a variety of asset classes and strategies.
Manish holds a Bachelors of Science in Cellular and Molecular Biology from The Johns Hopkins University and a Masters Degree in Financial Engineering from New York University.
How do I contact Manish Potti?
Has Manish Potti been buying or selling shares of Ocugen?
Manish Potti has not been actively trading shares of Ocugen within the last three months. Most recently, Manish Potti sold 68,185 shares of the business's stock in a transaction on Tuesday, June 15th. The shares were sold at an average price of $8.86, for a transaction totalling $604,119.10. Learn More on Manish Potti's trading history.
Who are Ocugen's active insiders?
Are insiders buying or selling shares of Ocugen?
In the last twelve months, Ocugen insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $9,100.00. The most recent insider tranaction occured on November, 26th when Director Prabhavathi Fernandes bought 10,000 shares worth more than $9,100.00. Insiders at Ocugen own 4.3% of the company.
Learn More about insider trades at Ocugen. Information on this page was last updated on 11/26/2024.
